Pacira | PCRX - Процентные расходы





Процентные расходы Изменить Дата
Assertio Holdings USD 758K 1000 2024-06
Astellas Pharma JPY 3.91B 320M 2025-03
Bristol-Myers Squibb USD 432M 48M 2025-12
Cara Therapeutics 39.02M 4.73M 2025-09
Coherus Biosciences USD 2.25M 76K 2025-12
Heron Therapeutics USD 600K 100K 2024-12
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
J&J USD 43M 25M 2026-03
Ligand Pharmaceuticals USD 910K 243K 2025-09
Nektar Therapeutics USD 9.77M 3.75M 2025-12
Novo Nordisk DKK 1.53B 3.43B 2025-09
Omeros USD 4.05M 5.16M 2024-09
Pacira USD 3.89M 387K 2025-12
Perrigo USD 10.08B 10.04B 2025-09
Pfizer USD 711M 59M 2025-12
Supernus Pharmaceuticals USD 910K 278K 2023-06
Teva Pharmaceutical Industries USD 220M 17M 2025-12
Xeris Pharmaceuticals USD 7.15M 115K 2025-12
Xoma USD 3.4M 150K 2024-06
Zoetis USD 57M 1000K 2025-12